Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06278883 · ClinicalTrials.gov registry record · NA
Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase
A NA study of Cancer and Cardiovascular Diseases, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 245
- Enrollment target
- 4
- Study locations
NCT06278883: Completed NA study of Cancer and Cardiovascular Diseases, sponsored by Duke University.
NCT06278883 is a NA study of Cancer and Cardiovascular Diseases that has completed, run by Duke University. The registered enrollment target is 245 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06278883, a NA study of Cancer and Cardiovascular Diseases, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 245 participants
- Enrollment target
- 4
- Study locations
Study Summary
The "Genomic medicine Risk Assessment Care for Everyone" (GRACE)" intervention project will develop a scalable end-to-end solution for risk assessment and management that meets the needs of those populations living in low resource settings. The long-term goal is to increase access to and uptake of risk-informed evidence-based guidelines that will improve population health through better patient outcomes, higher quality of life, and decreased costs. The three primary aims are: Aim 1: Develop a scalable implementation framework that guides each unique clinical setting, including low resource settings, in deploying GRACE effectively for the needs of their patients and providers. Aim 2: Facilitate the potential for genomic medicine to promote population health by broadening access to and uptake of genomic risk assessment by the general population through a pragmatic implementation-effectiveness trial of GRACE. Aim 3: Reduce health disparities related to genomic medicine by allowing individual adaption of GRACE to suit their level of resources, education, and access within a pragmatic implementation-effectiveness trial. Three sets of participants will be engaged: patients (n=750), providers (n=25), and family members of "probands" (i.e., patients that have a genetic change that increases risk, n\~500). Patient participants will be asked to complete a baseline survey, enter their family health history information into MeTree (a family health history web-based platform) and complete a survey about their experience using the platform. Subsequent study procedures will depend on: 1) the results of their MeTree risk evaluation, 2) their acceptance/declination of genetic testing (for those categorized as needing testing by MeTree), and 3) the results of the test (for those accepting testing). Provider participants will be providers who are the primary care physicians treating one or more patients enrolled in the patient participant group. Providers will be notified on a p
Primary Outcome
The number of participants completing MeTree relative to the number of participants who consented to the study.
Conditions Studied
Interventions
- BEHAVIORAL Disease Risk Assessment
Study Locations (4)
Florida
- UF Health Family Medicine - Lem Turner - Jacksonville
- UF Health Family Medicine - Commonwealth - Jacksonville
- UF Health Augustine Oaks - Jacksonville
- UF Health Oakleaf - Orange Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2025-09-10 |
| Phase | NA |
What the finished NCT06278883 record still lists
NCT06278883 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Disease Risk Assessment is the first listed.
NCT06278883 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06278883 about?
NCT06278883 is a clinical study titled "Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase". The "Genomic medicine Risk Assessment Care for Everyone" (GRACE)" intervention project will develop a scalable end-to-end solution for risk assessment and management that meets the needs of those populations living in low resource settings. The long-term goal is to increase access to and uptake of r...
What is the current status of trial NCT06278883?
This trial is currently completed. It is a NA study. The enrollment target is 245 participants. The study started on 2024-06-03. Estimated completion is 2025-09-10.
What conditions does trial NCT06278883 study?
This clinical trial studies the following conditions: Cancer, Cardiovascular Diseases, Liver Diseases, Hyperthermia.
What interventions are being tested in trial NCT06278883?
The interventions under investigation include: Disease Risk Assessment (BEHAVIORAL).
Who is sponsoring clinical trial NCT06278883?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06278883 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06278883's enrollment target sits among peer trials
245 209th of 615 higher than 407 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI